Nona Biosciences Forms Strategic Alliance with Invetx
Nona Biosciences, a prominent global biotechnology company dedicated to transformative solutions, has recently announced a strategic collaboration with Invetx, Inc., an innovative leader in animal biotechnology. This partnership aims to harness Nona's groundbreaking HCAb Harbour Mice technology to develop next-generation biotherapeutics tailored for animal health.
Innovative Technology Behind the Collaboration
The HCAb Harbour Mice technology stands out for its ability to generate monoclonal antibodies in two distinct formats: the conventional H2L2 and the innovative heavy chain-only (HCAb) format. The HCAb format is notably smaller than traditional IgGs, providing promising advantages in developing advanced antibody therapies. This technology is not only clinically validated but is also globally patented, showcasing its recognition and endorsement across the research community.
Comments from Leadership
Dr. Jingsong Wang, MD, PhD, who serves as the Chairman of Nona Biosciences, expressed enthusiasm about this collaboration, marking a pivotal moment as Nona ventures into the animal health sector. He highlighted the versatility and broad applicability of their Harbour Mice technology, aimed at empowering Invetx to pioneer novel therapeutics that cater to significant needs in animal health.
Similarly, Dr. Juergen Horn, DVM, PhD, the President of Invetx, shared his excitement about the partnership. He emphasized that utilizing Nona's HCAb technology would significantly expedite their clinical programs, focusing on validating the safety and efficacy of their advanced technology platforms.
About Nona Biosciences
Nona Biosciences is a forefront player in the biotechnology arena, committed to innovation that spans from initial ideas to investigational new drug applications. The company offers an array of integrated discovery solutions that encompass target validation, antibody discovery, preclinical research, and more. Their experienced team specializes in various methodologies, ensuring that their offerings remain comprehensive and cutting-edge.
Harbour Mice Technology Explained
The Harbour Mice platform employed by Nona Biosciences is engineered to produce fully human monoclonal antibodies in both classical two-light and two-heavy chain (H2L2) formats as well as the heavy chain-only (HCAb) format. This unique integration of platforms, including single B cell cloning, empowers Nona to drive global innovations in the realm of next-generation therapeutics.
About Invetx, Inc.
Invetx is at the forefront of veterinary medicine, aiming to transform care standards through the development of innovative, protein-based therapeutics. Their cutting-edge biotechnology platform facilitates the discovery, development, and manufacturing of veterinary monoclonal antibodies. Invetx is actively engaged in a diverse pipeline targeting chronic and severe health conditions in companion animals. Recently, Invetx was integrated into Dechra Pharmaceuticals Limited, thereby enhancing their capacity to advance veterinary pharmaceuticals.
Frequently Asked Questions
What is the focus of the Nona Biosciences and Invetx collaboration?
The collaboration aims to develop next-generation biotherapeutics for animal health using Nona's advanced HCAb Harbour Mice technology.
What are the benefits of the HCAb Harbour Mice technology?
This technology generates smaller, heavier chain-only antibodies that could enhance the efficacy of therapeutics by improving their targeting and reducing potential side effects.
Who are the key leaders involved in this partnership?
Dr. Jingsong Wang from Nona Biosciences and Dr. Juergen Horn from Invetx are the leading figures expressing their enthusiasm for this innovative collaboration.
What services does Nona Biosciences provide?
Nona Biosciences offers an extensive range of integrated solutions, including target validation, antibody discovery, and preclinical research, to support drug development.
How does this collaboration impact veterinary medicine?
This partnership is expected to accelerate the development of novel therapeutics that address critical health needs in companion animals, ultimately improving care standards in veterinary medicine.
